Symptom study app provides real-world data on COVID-19 vaccines.
Symptom study app provides real-world data on COVID-19 vaccines.
复制标题
DOI：
10.1016/s1473-3099(21)00264-4
复制
发表时间：
2021-07
期刊：
影响因子：
--
通讯作者：
O'Connor D
中科院分区：
文献类型：
--
作者：
Drury RE;O'Connor D
疫苗是控制COVID-19大流行的最佳机会。在大规模三期试验中显示出安全性和有效性的基础上，几种疫苗现已在多个国家获得批准。2020年12月8日，随着辉瑞- biontech mRNA疫苗（BNT162b2）的推出，COVID-19疫苗项目在英国启动。一个月内，牛津-阿斯利康ChAdOx1 nCoV-19 （AZD1222）腺病毒载体疫苗也投入使用。来自大规模接种后观察研究的令人信服的证据表明，在英国和以色列，COVID-19疫苗接种计划大大减少了COVID-19相关的住院治疗。此外，BNT162b2和ChAdOx1 nCoV-19似乎比有症状疾病（3期试验的主要终点）提供了更强的预防严重疾病的保护。5现在需要对COVID-19疫苗的安全性和有效性进行快速和详细的上市后监测，以便能够评估COVID-19疫苗接种规划的实际影响1,2，特别是考虑到令人关注的SARS-CoV-2变体的出现。6
Vaccines offer the best opportunity for bringing the COVID-19 pandemic under control. Several vaccines have now been authorised in multiple countries on the basis of demonstrated safety and efficacy in large-scale phase 3 trials. 1, 2 On Dec 8, 2020, the COVID-19 vaccine programme kicked off in the UK with the introduction of the Pfizer-BioNTech mRNA vaccine (BNT162b2). Within a month, the Oxford-AstraZeneca ChAdOx1 nCoV-19 (AZD1222) adenoviral vector vaccine had also been deployed. Compelling evidence from large-scale postimplementation observation studies has shown that COVID-19 vaccination programmes have substantially reduced COVID-19-related hospitalisation in the UK and Israel. 3, 4 Furthermore, BNT162b2 and ChAdOx1 nCoV-19 appear to offer greater protection against severe disease than symptomatic disease—the primary endpoint used in the phase 3 trials. 5 Rapid and detailed post-marketing surveillance of COVID-19 vaccine safety and effectiveness is now required to enable assessment of the realworld impact of COVID-19 vaccination programmes, 1, 2 particularly in light of the emergence of SARS-CoV-2 variants of concern. 6